Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of infection and febrile neutropenia in patients with solid cancer.
Virizuela JA, Carratalà J, Aguado JM, Vicente D, Salavert M, Ruiz M, Ruiz I, Marco F, Lizasoain M, Jiménez-Fonseca P, Gudiol C, Cassinello J, Carmona-Bayonas A, Aguilar M, Cruz JJ. Virizuela JA, et al. Clin Transl Oncol. 2016 Jun;18(6):557-70. doi: 10.1007/s12094-015-1442-4. Epub 2015 Nov 17. Clin Transl Oncol. 2016. PMID: 26577106
Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin.
Zaragoza-Huesca D, Rodenas MC, Peñas-Martínez J, Pardo-Sánchez I, Peña-García J, Espín S, Ricote G, Nieto A, García-Molina F, Vicente V, Lozano ML, Carmona-Bayonas A, Mulero V, Pérez-Sánchez H, Martínez-Martínez I. Zaragoza-Huesca D, et al. Among authors: carmona bayonas a. Biomed Pharmacother. 2023 Dec;168:115814. doi: 10.1016/j.biopha.2023.115814. Epub 2023 Oct 31. Biomed Pharmacother. 2023. PMID: 37918256 Free article.
Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells.
Rodenas MC, Peñas-Martínez J, Pardo-Sánchez I, Zaragoza-Huesca D, Ortega-Sabater C, Peña-García J, Espín S, Ricote G, Montenegro S, Ayala-De La Peña F, Luengo-Gil G, Nieto A, García-Molina F, Vicente V, Bernardi F, Lozano ML, Mulero V, Pérez-Sánchez H, Carmona-Bayonas A, Martínez-Martínez I. Rodenas MC, et al. Front Mol Biosci. 2023 May 19;10:1182925. doi: 10.3389/fmolb.2023.1182925. eCollection 2023. Front Mol Biosci. 2023. PMID: 37275957 Free PMC article.
Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, Ramchandani A, Martínez J, Hernando Cubero J, Espinosa J, Martínez de Castro E, Ghanem I, Beato C, Blasco A, Garrido M, Bonilla Y, Mondéjar R, Arcusa Lanza MÁ, Aragón Manrique I, Manzano A, Sevillano E, Castañón E, Cardona M, Gallardo Martín E, Pérez Armillas Q, Sánchez Lasheras F, Ayala de la Peña F. Carmona-Bayonas A, et al. J Clin Oncol. 2015 Feb 10;33(5):465-71. doi: 10.1200/JCO.2014.57.2347. Epub 2015 Jan 5. J Clin Oncol. 2015. PMID: 25559804
[Pulmonary embolism in patients with cancer: foundations of the EPIPHANY study].
Font C, Carmona-Bayonas A, Plasencia JM, Calvo-Temprano D, Sánchez M, Jiménez-Fonseca P, Beato C, Biosca M, Vicente V, Otero R; en representación de los Investigadores del Proyecto EPIPHANY. Font C, et al. Med Clin (Barc). 2015 Jan;144 Suppl 1:31-7. doi: 10.1016/S0025-7753(15)30016-6. Med Clin (Barc). 2015. PMID: 25771090 Spanish.
Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P, Carmona-Bayonas A, Martín-Pérez E, Crespo G, Serrano R, Llanos M, Villabona C, García-Carbonero R, Aller J, Capdevila J, Grande E; Spanish Neuroendocrine Tumor Group (GETNE). Jiménez-Fonseca P, et al. Cancer Metastasis Rev. 2015 Sep;34(3):381-400. doi: 10.1007/s10555-015-9573-1. Cancer Metastasis Rev. 2015. PMID: 26245646 Review.
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.
Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, Grande E, Capdevila J, Aller J, Arbizu J, Jimenez-Fonseca P; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE). Garcia-Carbonero R, et al. Cancer Metastasis Rev. 2015 Dec;34(4):823-42. doi: 10.1007/s10555-015-9598-5. Cancer Metastasis Rev. 2015. PMID: 26433592 Free PMC article. Review.
A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia.
Fonseca PJ, Carmona-Bayonas A, García IM, Marcos R, Castañón E, Antonio M, Font C, Biosca M, Blasco A, Lozano R, Ramchandani A, Beato C, de Castro EM, Espinosa J, Martínez-García J, Ghanem I, Cubero JH, Manrique IA, Navalón FG, Sevillano E, Manzano A, Virizuela J, Garrido M, Mondéjar R, Arcusa MÁ, Bonilla Y, Pérez Q, Gallardo E, Del Carmen Soriano M, Cardona M, Lasheras FS, Cruz JJ, Ayala F. Fonseca PJ, et al. Br J Cancer. 2016 May 24;114(11):1191-8. doi: 10.1038/bjc.2016.118. Epub 2016 May 17. Br J Cancer. 2016. PMID: 27187687 Free PMC article.
On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism.
Carmona-Bayonas A, Font C, Jiménez-Fonseca P, Fenoy F, Otero R, Beato C, Plasencia J, Biosca M, Sánchez M, Benegas M, Calvo-Temprano D, Varona D, Faez L, Vicente MA, de la Haba I, Antonio M, Madridano O, Ramchandani A, Castañón E, Marchena PJ, Martínez MJ, Martín M, Marín G, Ayala de la Peña F, Vicente V; Asociación de Investigación de la Enfermedad Tromboembólica de la Región de Murcia. Carmona-Bayonas A, et al. Thromb Res. 2016 Jul;143:76-85. doi: 10.1016/j.thromres.2016.05.010. Epub 2016 May 12. Thromb Res. 2016. PMID: 27208461
143 results